Clinical year in review of COPD for pulmonary physicians

Tuberculosis and Respiratory Diseases

Volumn 64, Issue 6, 2008, Pages 409-413

  Oh, Yeon Mok ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE;

AIR QUALITY; AMBIENT AIR; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; QUESTIONNAIRE; REVIEW; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT OUTCOME;

EID: 47149088505     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2008.64.6.409     Document Type: Review

References (11)

1. Korea National Statistical Office, Republic of Korea [Internet]. Daejeon: Korea National Statistical Office; c1996- [cited 2008 Mar]. Available from: http://www.nso.go.kr.
2. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-7.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
5. PubMed [Internet]. Bethesda (MD): National Library of Medicine (US). [1950] - [cited 2008 Mar]. Available from: http://www.ncbi.nlm.nih.gov/sites/ entrez.
6. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007;62:237-41.
7. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55.
8. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansah Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
9. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61.
10. Osman LM, Douglas JG, Garden C, Reglitz K, Lyon J, Gordon S, et al. Indoor air quality in homes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:465-72.
11. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-5.